By Josh White
Date: Monday 23 Jun 2025
(Sharecast News) - Oxford Biomedica said on Monday it has acquired the remaining 10% stake in its US subsidiary, OXB US, from Q32 Bio, bringing its ownership of the business to 100% as previously planned.
By Josh White
Date: Monday 23 Sep 2024
(Sharecast News) - Oxford Biomedica, a prominent gene and cell therapy company, reported significant revenue growth alongside strategic advancements in its interim results on Monday.
By Josh White
Date: Thursday 08 Aug 2024
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation Oxford Biomedica reported a strong first-half trading performance in an update on Thursday, with revenue expected to reach £50m.
Currency | UK Pounds |
Share Price | 352.00p |
Change Today | -1.00p |
% Change | -0.28 % |
52 Week High | 445.00p |
52 Week Low | 232.50p |
Volume | 200,824 |
Shares Issued | 106.14m |
Market Cap | £373.60m |
Beta | 0.00 |
RiskGrade | 125 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 3 |
Buy | 2 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 9 |
No dividends found |
Time | Volume / Share Price |
15:20 | 141 @ 354.00p |
16:35 | 36,237 @ 352.00p |
16:35 | 95 @ 352.00p |
16:35 | 191 @ 352.00p |
16:35 | 303 @ 352.00p |
Chair | Roch Doliveux |
CEO | Frank Mathias |
CFO | Lucinda (Lucy) Crabtree |
You are here: research